Redirecting Antigen Specificity to Nonspecific CD8+25+ Regular T Cells Through Antigen-Specific Peptide/mhc Complex Arming. (P1085)

Lu Wang,Xueshu Zhang,Sean J. Mulligan,Jim Xiang
DOI: https://doi.org/10.4049/jimmunol.190.supp.121.14
2013-01-01
Abstract:Compared with CD4+25+ regulatory T (Tr) cells, the mechanisms for immune suppression of natural CD8+25+ Tr cells are less studied. In this study, we demonstrate that CD8+25+ Tr cells inhibit in vitro T cell proliferation via cell-contact fashion, but independent upon expression of suppressive IL-10, TGF-β and CTLA-4. CD8+25+ Tr-treated T cells express CD73 and FR-4 and become resistant to cell proliferation by dendritic cell (DC) stimulation, whereas CD8+25+ Tr-treated DCs down-regulate expression of DC-maturation markers and inflammatory cytokines, and lack stimulatory effect on T cell proliferation. CD8+25+ Tr cells suppress ovalbumin (OVA)-pulsed DC (DCOVA)-stimulated CD8+ cytotoxic T lymphocyte (CTL) responses and antitumor immunity as well as myelin oligodendrocyte glycoprotein (MOG) peptide-induced experimental autoimmune encephalomyelitis (EAE). Importantly, CD8+25+ Tr cells, when pulsed with OVA323-339 and MOG35-55 peptide, exert enhanced inhibition of antitumor immunity and EAE, respectively. Interestingly, OVA323-339-pulsed (armed) CD8+25+ Tr cells also reduce CD4+ T cell interactions with DCOVA via increasing CD4+ T-cell velocities assessed by two-photon microscopy. Therefore, redirecting antigen specificity to nonspecific CD8+25+ Tr cells for enhanced immune suppression can be achieved via antigen-specific peptide/MHC complex arming. This principle may have great impact in natural Tr cell-mediated immunotherapy for autoimmune diseases.
What problem does this paper attempt to address?